Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
First, I have no interest in sharing the pros and cons because it’s useless talking to rocks. Second, some of us aren’t “sad” because we went in knowing the risk here. No need to cry if one does that. Apparently some of you don’t. Third, why would an insider like staelin keep loaning his hard earned money if this was a useless venture? Figure it out. Fourth, there has never been a reverse split which says a lot about how they value investors. Andy promised no split and Kelly has honored that. A split would have been the death knell here. Lastly if the company fails, Kelly and family, as well as staelin, would lose big time. So stop trashing the company with the daily whining and let it play out. Forget about the stock. Put it on the back burner if the pressure of watching is too great . It will either fail or not. Then there’s always selling and taking the tax loss. Then you won’t have to worry about it any longer.
In regards to SRINSOCAL, please be careful who you refer to as scam artist.
BECAUSE SRIN WAS NOT THE ONE FIRED AS AN EMPLOYEE FROM BIEL.
BIOELECTRONICS is for real and there ain’t anything you can do to stop it.
Buy/Sell ratio is much more useful than your '6 trades with .0001 on the Bid' BS
Another 16.4 million shares Shorted today with 483 million shares on the Bid Size and 157 million shares on the Ask Size.
Date ..... Symbol .. Short vol .. Total vol
20240426 | BIEL | 16485000 | 28245000
We made it through the week without BK thats great. Little to no sales of trinket does not help float the ship. 700 plus K in a year of trinket sales is a joke. Hope they strike a deal that can keep them a float.
STOP PRETENDING
C'MON, this BUY / SELL constant reference is a joke when you are talking about a 'BUY' that's .0002. YES, that .0002 is a joke of a stock price and somehow we are trying to make it a POSITIVE? Do all the justification you want of why this is trading at rock bottom, ie about MM's and about all those shorting this stock (naked or not), because there is NO sugar coating or justifying the fact that this IS trading at the lowest in the history of this company and at ROCK BOTTOM.
Again maybe this is trading so low because of the facts in the financials. ------ Ya think THAT might be the reason and NOT the MM's playing games?
From the UCSD statements on the Postoperative Analgesia Study
"Study intervention. The pulsed shortwave device (2 devices, if there are multiple incisions or the incision is larger than the device diameter; 3 devices for total knee and hip arthroplasty or spinal surgery) will be affixed over the primary wound area(s) using tape and activated prior to recovery room discharge (Experimental). The optimal location to treat phantom pain is currently unknown and will partially informed by the results of this pilot study, and patients will be encouraged to move the devices to a new anatomic location until relief is optimized."
"Specific Aim 2: To estimate the treatment effect of adding nonthermal, pulsed shortwave therapy to usual and customary analgesia on pain and opioid consumption following moderate-to-severely painful surgical procedures."
"Hypothesis 2: Nonthermal, pulsed shortwave therapy decreases opioid use in the 7 days following moderate-to-severely painful surgical procedures."
"The two outcomes of primary interest will be (1) the "average" and "worst" pain measured with the Numeric Rating Scale (included in the Brief Pain Inventory pain domain), and (2) opioid consumption within the first 7 postoperative days."
"Treatment with BioElectronics Model 088"
"Status - in progress, not accepting new patients
Start Date - July 2022
Completion Date - April 3, 2024 (estimated)
Sponsor - University of California, San Diego
ID - NCT05399355
Study Type - Interventional
Participants - About 120 people participating
Last Updated - February 8, 2024"
https://clinicaltrials.ucbraid.org/trial/NCT05399355
They can't sell what's on the table now, so what good are more worthless trials?
Dr. Staelin’s update stated “We have two investigator sponsored clinical trials now in the field. The first is a surgical analgesia trial being conducted at the University of San Diego…Thus, the study will be able to assess the efficacy of our model 088 in not only reducing the acute surgical pain and opioid use, but also reducing or even eliminating any chronic pain resulting from surgery.”
Efficacy is the key word (and seems that’s been “tossed” around here too): it’s the ability to produce a desired or intended result (e.g. reduced opioid use). That’s what we want.
This is a major study, and an important Clinical Trial.
If a “Study” says an intervention is to be used (model 088/Actipatch/RecoveryRx) with the hypothesis that the intervention will result in reduced opioid use, that’s what the FDA is looking for. If it doesn’t as in a Pilot Study without an intervention, that study may still spur other clinical trials, so it’s not a nothinburger.
Do not be fooled by the use of “Study” terminology as a means to minimize its importance.. If it calls for an intervention, it’s a clinical trial.
terminology…
What are the types of clinical research?
There are 2 main types of clinical research:
* Clinical trials, also called interventional studies
* Observational studies
Both may try to learn more about an intervention, which may be a drug, behavior, or medical device. The main difference is clinical trial participants are assigned to get an intervention, but observational study participants are not assigned to get an intervention.
https://clinicaltrials.gov/study-basics/learn-about-studies
The NOPAIN Act and CMS insurance reimbursement of 1/2025 given BIEL’s clinical studies and interventional products showing efficacy and reduced narcotic/opioid usage…should the green light shine…some won’t like it. Some are gonna love it.
I like the BIEL wildcard.
imo
A more accurate April 26 view, Buys @ 2 Outnumber Sells @ 1 by a 3 to 1 Margin
Buys = 21.7 million shares
Sells = 6.1 million shares
Neutral = 407k shares
Closing SP = .00015
Scroll down to the second “study”
https://www.bielcorp.com/clinical-evidence/postoperative-pain-edema/
Control of Postoperative Pain with a Wearable Continuously Operating Pulsed Radiofrequency Energy Device: A Preliminary Study
Ian M. Rawe, Adam Lowenstein, C. Raul Barcelo & David G. Genecov
BioElectronics RecoveryRx® was investigated in a double blind, randomized and placebo controlled study for postoperative pain and narcotic pain medication use following breast augmentation surgery. Data, VAS pain scores (0-10) and medication was collected for seven days post-surgery. The group using RecoveryRx® experienced 50% less pain and consumed significantly less narcotic pain medications. The study is published in the Aesthetics of Plastic Surgery.
Oh, for those that get stuck on “study” vs clinical trial…
It’s been noted by some that because “Study” terminology is used, it is therefore not a clinical trial.
terminology…
What are the types of clinical research?
There are 2 main types of clinical research:
* Clinical trials, also called interventional studies
* Observational studies
Both may try to learn more about an intervention, which may be a drug, behavior, or medical device. The main difference is clinical trial participants are assigned to get an intervention, but observational study participants are not assigned to get an intervention.
https://clinicaltrials.gov/study-basics/learn-about-studies
For the forum…
Question of the day, or maybe everyday from now until start of the NOPAIN Act and CMS insurance reimbursement 1/2025…
Was this “study” surgery-related, and an intervention used, and if so, is it BIEL’s product, and lastly, does this preliminary “study” qualify as a bona fide clinical trial or will someone have a beef with “preliminary” too?
Yes that cancer treatment is looking strong (leading up to the news, anyway) and I know you are also invested in that. But my OTHER cancer diagnostic had its catalyst delayed nine months. That PPS is going to suffer this year. The saving grace is that the O/S is under 60 million and insiders own about half of the stock. It's still going to be painful to watch that paint dry for the next nine months.
In BIELworld, I think Ilfeld will announce results of his opioid pilot study soon, and that is an important catalyst for BIEL because they have no other clinical proof that their device reduces opioid use. BIEL investors are pinning their hopes and dreams on the NOPAIN Act but at this moment BIEL is on the sidelines looking in.
And on FB the band plays on. The newest pumper thinks BIEL should increase the price of the ActiPatch to $99, contrary to the Law of Supply and Demand, the most basic tenet of every economist everywhere. Ahhh but what do economists know. This new pumper also thinks BIEL should sue the maker of the Assisi Loop and take over that market, and also offered to lend the company money if they would manipulate the share price for him. Gotta love the energy, I guess.
It is hard to understand how someone who honestly believes that the system is rigged so strongly against them would even consider being in this market.
Ce la vie, and to each their own.
p.s. that cancer treatment you are/were invested in is looking strong lately!
.0001.
April 26th, 2024--Biel trades at .0001.
yet do you dream hope, yet do you poke and disparage?
it is wild...
Solid facts. Thank you.
-Yes
>>>It’s a special kind of special when one continues to provide negative information that we are all aware of.<<<
The information I provide comes from the financials that the company posts (when they feel like posting them). Some may not understand them, so I try to point out the numbers and what they mean and why they are a major reason why this is trading where it is. The ones that are trying to convince ANYONE that this is a good investment or tries to ignore those numbers needs to understand financials. The fact that this leadership has now (it seems) decided to stop reporting quarterly anymore only reinforces their lack of stockholder compassion. Having to wait a whole year to see the financials and evaluate the company as an investment, has to be nothing but concerning to the stockholders, ---- as the stock price reflects. It (financial statements) is and always will be the main source for company evaluation for ones investment. One can assume, THAT is the reason for the CEO's decision for such (ie. they are that bad?)
hey threep.
there isn't anybody who posts about Biel who isn't sad. including me.
the pps now trades between .0001 and .0002.
the CEO has been m.i.a. for years now.
the company is sustained by a Dr. Staelin, who for impenetrable reasons is willing to loan biel
significant amounts of his own money.
the share structure poses an insurmountable obstacle.
the products haven't gained traction in twenty years.
there are massive debts, warrants galore, tens of billions of discounted shares possessed by the whelans,
who from the outset until now, manage to stay under the sec's radar, though they have managed the
company like a family-owned business, not a publicly traded company.
there is so much more to say against Biel, but again, because human nature can be an impenetrable mystery,
a couple dozen longs hang in and argue the pros and cons of this non-entity.
it could literally file chapter 11 any minute, hour, day...
It's puzzling how people get labeled as "bashers" just for presenting factual information about a stock that may appear negative to investors, merely because it challenges their beliefs or opinions.
-Yes
Just concentrate on your bashing skills. It’s a special kind of special when one continues to provide negative information that we are all aware of. Are you trying to protect potential investors. Are you trying to upset those already invested? Or you just frustrated because you have no control of the narrative here? Or is it just retired with nothing better to do? That’s kinda sad.
Ah yes toohot, a member of BIEL'S ihub pump squad joins in.
The fact is you're a message board scam artist that tries so hard to justify this company's worthless existence, no matter what.
Thank you, Three. Thought provoking BIEL post. Nice job!
>>>Amazing that you always bring facts and you’re met with the whiney defenses of negativity. <<<<
Maybe because despite all that is posted, the stock price still trades at rock bottom and the financials show another net loss AGAIN, continuing its streak of NEVER profitable, not one year in over 20 years in business. Plus sales that have dropped over the years. Plus an asset to liability ratio that has remained laughably weighted to the liability side ($144,388 : $16,622,807). Plus over $12,000,000 in note/loans that have matured and could not be paid back thus remain on the books. Plus those balance sheet financials showing a cumulative deficit of over $39,000,000. Plus cash flow from operations for the year of -$722,812. Plus authorized shares not enough to satisfy all the note/loan to stock conversions. Plus with all that is due ($), they have 'cash on hand' at time of financials, of $4686!
Maybe that is why the negativity! ----- YA THINK?
Amazing that you always bring facts and you’re met with the whiney defenses of negativity. How do we know? When all else fails, throw out the r/s scare. Such juvenile arguments that NEVER work. The obvious fact is that some just don’t want this to succeed. That’s their problem.
LOL Counterfeiting biel would be like counterfeiting pennies. Why bother. LMAO
I hope you didn't buy too much. It's going lower.
LOL so you think I own counterfeit shares?
News flash for you -- I'll buy more at .0001 if the MM's will sell them to me. And then I'll flip them for a profit. And I'll make money doing this and I'll laugh all the way to the bank.
And the BIEL longs will call me a dirty nasty flipper and you'll wail and gnash your teeth about poor little abused BIEL and those evil MM's.
And I won't care.
The only way I can lose money here is if I hold this hot potato too long and get surprised by the Reverse Split announcement that we all know is coming. There will be a stampede for the door as, what's your favorite saying, "anyone with half a brain" tries to sell at .0001.
That's the game here -- don't get caught holding the bag when they announce the R/S. Don't be one of the half-wits who hold BIEL too long with those "strong hands."
A disgruntled employee will not support the company, makes people wonder why there was a firing.
This will help you understand the system
<<<<<< Funny, that stock didn't materialize out of thin air >>>>>>
Counterfeiting Stock 2.0
Illegal naked shorting and stock manipulation are two of Wall Street’s deep, dark secrets.
These practices have been around for decades and have resulted in trillions of dollars being
fleeced from the American public by Wall Street. In the process, many emerging companies have
been put out of business. This report will explain the magnitude of this problem, how it happens,
why it has been covered up and how short sellers attack a company. It will also show how all of
the participants; the short hedge funds, the prime brokers and the Depository Trust Clearing
Corp. (DTCC) - make unconscionable profits while the fleecing of the small American investor
continues unabated.
Why is This Important? This problem affects the investing public. Whether invested directly in
the stock market or in mutual funds, IRAs, retirement or pension plans that hold stock – it
touches the majority of Americans.
The participants in this fraud, which, when fully exposed, will make Enron look like child’s
play, have been very successful in maintaining a veil of secrecy and impenetrability. Congress
and the SEC have unknowingly (?) helped keep the closet door closed. The public rarely knows
when its pocket is being picked as unexplained drops in stock price get chalked up to “market
forces” when they are often market manipulations.
The stocks most frequently targeted are those of emerging companies who went to the stock
market to raise start-up capital. Small business brings the vast majority of innovative new ideas
and products to market and creates the majority of new jobs in the United States. It is estimated
that over 1000 of these emerging companies have been put into bankruptcy or had their stock
driven to pennies by predatory short sellers.
It is important to understand that selling a stock short is not an investment in American
enterprise. A short seller makes money when the stock price goes down and that money comes
solely from investors who have purchased the company’s stock. A successful short manipulation
takes money from investment in American enterprise and diverts it to feed Wall Street’s
insatiable greed - the company that was attacked is worse off and the investing public has lost
money. Frequently this profit is diverted to off-shore tax havens and no taxes are paid. This
national disgrace is a parasite on the greatest capital market in the world.
10. Fails-to-Deliver – The process of creating shares via naked shorting creates an obvious
imbalance in the market as the sell side is artificially increased with naked short shares or
more accurately, counterfeit shares. Time limits are imposed that dictate how long the
sold share can be naked. For a stock market investor or trader, that time limit is three
days. According to SEC rules, if the broker dealer has not located a share to borrow, they
are supposed to take cash in the short account and purchase a share in the open market.
This is called a “buy-in,” and it is supposed to maintain the total number of shares in the
market place equal to the number of shares the company has issued.
Market makers have special exemptions from the rules: they are allowed to carry a
naked short for up to twenty-one trading days before they have to borrow a share. When
the share is not borrowed in the allotted time and a buy-in does not occur, and they rarely
do, the naked short becomes a fail-to-deliver (of the borrowed share).
The Creation of Counterfeit Shares – There are a variety of names that the securities industry
has dreamed up that are euphemisms for counterfeit shares. Don’t be fooled: Unless the short
seller has actually borrowed a real share from the account of a long investor, the short sale is
counterfeit. It doesn’t matter what you call it and it may become non-counterfeit if a share is later
borrowed, but until then, there are more shares in the system than the company has sold.
The magnitude of the counterfeiting is hundreds of millions of shares every day, and it may
be in the billions. The real answer is locked within the prime brokers and the DTC. Incidentally,
counterfeiting of securities is as illegal as counterfeiting currency, but because it is all done
electronically, has other identifiers and industry rules and practices, i.e. naked shorts, fails-todeliver, SHO exempt, etc. the industry and the regulators pretend it isn’t counterfeiting. Also,
because of the regulations that govern the securities, certain counterfeiting falls within the letter
of the rules. The rules, by design, are fraught with loopholes and decidedly short on allowing
companies and investors access to information about manipulations of their stock.
https://www.sec.gov/comments/s7-07-23/s70723-20162302-331156.pdf
Every Year, Like a Broken Record
"BIEL is finished"
"No way BIEL survives SEC"
"No way BIEL gets FDA Reclassification"
"No way BIEL gets Plantar Fasciitis Clearance"
"No way BIEL gets Knee Osteoarthritis Clearance"
"No way BIEL gets OTC Clearance"
"No way BIEL gets CE Mark"
"No way BIEL gets Musculoskeletal Clearance"
"No way BIEL gets Post-Op Pain Clearance"
"Andy told me BK coming"
"Andy told me RS coming"
Always Wrong
Such a shame that MM's abuse only BIEL.
No other OTC stock gets manipulated by Market Makers -- it's just BIEL. Poor abused manipulated little BIEL. It's so unfair.
Incidentally I bought some BIEL at .0001 during that shocking Market Maker Abuse this week, so for the first time since 2020 I once again own BIEL stock. I guess that means I can now call Kelly Whelan and suffer her abuse.
And to think that if the MM's didn't illegally sell me stock at .0001, I wouldn't be a shareholder! Funny, that stock didn't materialize out of thin air -- SOMEBODY sold it...... hard to reconcile the FACT that I bought this stock at .0001 with your story of MM's selling stock they don't have.
This "miracle" product has not sold for the last 10 years, whatever the business model (OEM, in house marketing, distributors, you name it). Andy Wheelan is probably sitting in his grave and feeling disappointed that his heirs have not found the solution he has been looking for for years.
edbi-Happy Friday! What a great post. Thank you for sharing.
# 2 is my favorite:
NOPAIN Act
https://www.congress.gov/bill/117th-congress/house-bill/3259/text?s=2&r=1&q=%7B%22search%22%3A%22NOPAIN+ACT%22%7D
Just to highlight a few points::
(G) ACCESS TO NON-OPIOID TREATMENTS FOR PAIN.—
“(i) IN GENERAL.—
Notwithstanding any other provision of this subsection, with respect to a covered OPD service (or group of services) furnished on or after January 1, 2022, and before January 1, 2027, the Secretary shall not package, and shall make a separate payment as specified in clause (ii) for, a non-opioid treatment (as defined in clause (iii)) furnished as part of such service (or group of services).
“(ii) AMOUNT OF PAYMENT.—
The amount of the payment specified in this clause is, with respect to a non-opioid treatment that is—
“(I) a drug or biological product, the amount of payment for such drug or biological determined under section 1847A; or
<<<<" II) a medical device, the amount of the hospital’s charges for the device, adjusted to cost.
“(iii) DEFINITION OF NON-OPIOID TREATMENT.
A ‘non-opioid treatment’ means—
“(I) a drug or biological product that is indicated to produce analgesia without acting upon the body’s opioid receptors; or
“(II) an implantable, reusable, or disposable medical device cleared or approved by the Administrator for Food and Drugs for the intended use of managing or treating pain;
that has demonstrated the ability to replace, reduce, or avoid opioid use or the quantity of opioids prescribed in a clinical trial or through data published in a peer-reviewed journal.”.>>>>
(b) Ambulatory Surgical Center Payment System.—Section 1833(i)(2)(D) of the Social Security Act (42 U.S.C. 1395l(i)(2)(D)) is amended—
(1) by aligning the margins of clause (v) with the margins of clause (iv);
(2) by redesignating clause (vi) as clause (vii); and
(3) by inserting after clause (v) the following new clause:
“(vi) In the case of surgical services furnished on or after January 1, 2022, and before January 1, 2027, the payment system described in clause (i) shall provide, in a budget-neutral manner, for a separate payment for a non-opioid treatment (as defined in clause (iii) of subsection (t)(16)(G)) furnished as part of such services in the amount specified in clause (ii) of such subsection.”.
(c) Evaluation Of Therapeutic Services For Pain Management.—
1) REPORT TO CONGRESS.—
Not later than 1 year after the date of the enactment of this Act, the Secretary of Health and Human Services (in this subsection referred to as the “Secretary”), acting through the Administrator of the Centers for Medicare & Medicaid Services, shall submit to Congress a report identifying—
(A) limitations, gaps, barriers to access, or deficits in Medicare coverage or reimbursement for restorative therapies, behavioral approaches, and complementary and integrative health services that are identified in the Pain Management Best Practices Inter-Agency Task Force Report and that have demonstrated the ability to replace or reduce opioid consumption; and
(B) recommendations to address the limitations, gaps, barriers to access, or deficits identified under subparagraph (A) to improve Medicare coverage and reimbursement for such therapies, approaches, and services.>>>>
(2) PUBLIC CONSULTATION
.—In developing the report described in paragraph (1), the Secretary shall consult with relevant stakeholders as determined appropriate by the Secretary.
(3) EXCLUSIVE TREATMENT.
—Any drug, biological product, or medical device that is a non-opioid treatment (as defined in section 1833(t)(16)(G)(iii) of the Social Security Act, as added by subsection (a)) shall not be considered a therapeutic service for the purpose of the report described in paragraph (1).
___________________________________________________________
A study investigating the efficacy of our FDA-cleared (human use) pulsed-shortwave-therapy (PSWT) device in initiating a systemic anti-inflammatory response to improve the functionality of canines diagnosed with osteoarthritis. 96% of the treatment group showed either increased passive range of motion, improved behavioral changes, or both compared to 4% for the placebo group. It was published today online in "Veterinary Medicine and Science." Medical professionals can contact us at info @newbie00 to request sample products.
Pulsed shortwave electromagnetic field therapy increases quality of life in canines with symptoms of osteoarthritics
Tanya Ella Sprunks, Kenneth J. McLeod, Richard Staelin
First published: 22 March 2024 https://doi.org/10.1002/vms3.1408
Sree Koneru and Jack Merrifield contributed equally to this study.
https://onlinelibrary.wiley.com/doi/10.1002/vms3.1408
--------------------------------------------------------------------------------------------------
Actipatch ranked #1 in NASA Electromagnetic Pain Relief/Blocking: Feasibility Assessment !!!!!!!!
National Aeronautics and Space Administration
Lyndon B. Johnson Space Center
Houston, Texas 77058
( pages 14, 15 )........
Context/Background:
Astronauts use pharmaceuticals during spaceflight to manage acute and chronic pain, but use of analgesics will have drawbacks for exploration-class missions because the shelf life of these medications is limited, resupply will be curtailed, astronauts may develop tolerance and/or addiction to these medications, and side effects can include impairment of
cognitive abilities. Electromagnetic devices have been developed that treat pain terrestrially by affecting neuromodulation–dubbed “electroceuticals”, these devices have varied mechanisms of action that either stimulate or suppress neural activity in the central nervous system or peripheral nerves.
Objective/Purpose:
The available literature was reviewed and FDA-approved pain treatments (both pharmacological and non-pharmacological), as well as those currently under development, were assessed for their suitability for use in exploration class spaceflight missions.
Results:
An overwhelming majority of the literature focuses on the treatment of chronic rather than acute pain because it is assumed that acute pain only rarely fails to resolve and instead transitions into chronic pain when the central nervous system becomes hypersensitized. The available electromagnetic devices marketed for pain treatment have varying levels of
invasiveness, use different mechanisms of action, and have demonstrated varying efficacy when evaluated scientifically. A truly noninvasive, highly efficient device is desired for use during spaceflight. One portable, self-contained, FDA-approved device was identified that, from preliminarily assessment, best met these criteria; the device noninvasively applies pulsed
shortwave therapy (PSWT) to modify pain signals from peripheral nerves, however, the device has limited battery life and the effects are relatively non-selective in type of neural signal modified.
Ranking:
The treatment method ranked first in this review was pulsed
shortwave therapy (PSWT), a low-power RF (MHz range) transmitter operated adjacent to biological tissue at maximum output (saturation) to modulate peripheral nerve activity. ActiPatch is a very small wearable PSWT device that is FDA approved for “adjunctive treatment of musculoskeletal pain”
[Anwar-Deen 2020]. It is low cost, low power, and boasts 97% efficacy in reducing pain (85% over a 6-month period) [Staelin 2019]. The device can be secured to the body by physio tape and the area causing pain is bounded by the device’s ring. The device can be turned on and off, and the non-rechargeable battery is capable of 720 hours of operation
(one month continuous use). ActiPatch is sold OTC in local pharmacies for ~$30 [ActiPatch 2020].
Conclusions:
The information obtained in the execution of this review effort leads to 2 recommendations for forward work:
1. Tie into DoD and NIH research funding efforts to improve pain treatment: the NIH has a federal partners workgroup for their HEAL Initiative that could conceivably be joined by NASA, and the DoD CPMRP’s initial solicitation only recently completed so that program is young and potentially synergies could be identified with NASA.
2. Obtain an ActiPatch device for evaluation and determine whether it could be beneficial and adapted to spaceflight use.
https://ntrs.nasa.gov/api/citations/20205008893/downloads/2020ICA_Mullenax_report_24Sep20.pdf
_________________________________________________________
? iAsk.AI ( Thank you, Probity!!! )
Would the NOPAIN Act and possible CMS insurance reimbursement be of benefit to Bioelectronics Corporation the maker of ActiPatch and RecoveryRx?
According to www.iAsk.ai Ask Ai Answer Engine:
Benefits of the NOPAIN Act and CMS Insurance Reimbursement for Bioelectronics Corporation
The NOPAIN Act, which stands for Non-Opioids Prevent Addiction in the Nation Act, aims to improve access to non-opioid pain management treatments for Medicare beneficiaries. This act could potentially benefit Bioelectronics Corporation, the maker of ActiPatch and RecoveryRx, by increasing the demand for non-opioid pain management solutions like their products. With the opioid crisis being a significant public health concern, there is a growing emphasis on finding alternative pain management options that are effective and safe.
Impact of the NOPAIN Act on Bioelectronics Corporation
Increased Demand: The implementation of the NOPAIN Act could lead to increased demand for non-opioid pain management products like ActiPatch and RecoveryRx. Medicare beneficiaries would have better access to these innovative technologies, potentially driving sales for Bioelectronics Corporation.
Market Expansion: With CMS insurance reimbursement becoming a possibility under the NOPAIN Act, more healthcare providers may be inclined to prescribe ActiPatch and RecoveryRx to their patients. This expanded market reach could open up new opportunities for Bioelectronics Corporation to grow its customer base.
Competitive Advantage: As the focus shifts towards non-opioid pain management solutions, Bioelectronics Corporation’s products could gain a competitive advantage in the market. Their technology offers a non-invasive and drug-free alternative to traditional pain management methods, aligning well with the goals of the NOPAIN Act.
Overall Benefit to Bioelectronics Corporation
In conclusion, the NOPAIN Act and potential CMS insurance reimbursement could indeed be beneficial to Bioelectronics Corporation. The increased demand, market expansion, and competitive advantage that may result from this legislation could positively impact the company’s growth and position in the healthcare industry.
Top 3 Authoritative Sources Used:
Centers for Medicare & Medicaid Services (CMS): Information from CMS was crucial in understanding how insurance reimbursement policies can impact healthcare providers and medical device companies like Bioelectronics Corporation.
National Institutes of Health (NIH): NIH research on pain management alternatives and opioid addiction provided valuable insights into the importance of non-opioid solutions like ActiPatch and RecoveryRx.
American Society of Anesthesiologists (ASA): The ASA’s stance on opioid addiction and their support for non-opioid pain management strategies helped in evaluating the potential benefits of the NOPAIN Act for companies like Bioelectronics Corporation.
________________________________________________________
Accelerated recovery of post-operative dental implant patients using drug-free RecoveryRx.
Read the paper here:
https://lnkd.in/daQ4GRa
#painrelief #neuromodulation #fdacleared #drugfree #clinicallyproven #painmanagement #oralsurgery #dentalimplants #postsurgical
https://www.linkedin.com/posts/bioelectronics-corporation_painrelief-neuromodulation-fdacleared-activity-6778677760979152896-XQZ1
___________________________________________________________________
CA OrthoAlliance
Solutions for Optimal Patient Outcomes
RecoverRX
https://orthoalliance.com/solutions-for-optimal-patient-outcomes/
_______________________________________________________________
BioElectronics Chairman Updates Investors
Thu, February 15, 2024 at 9:00 AM EST
https://finance.yahoo.com/news/bioelectronics-chairman-updates-investors-140000529.html
______________________________________________________________
Voices for Non-Opioid Choices Coalition Applauds Introduction of Alternatives to PAIN Act in Senate
https://www.prnewswire.com/news-releases/voices-for-non-opioid-choices-coalition-applauds-introduction-of-alternatives-to-pain-act-in-senate-302076547.html
____________________________________________________________
CHEMIST4u ( UK )
ActiPatch Muscle and Joint Pain Therapy Devices
https://www.chemist-4-u.com/brands/actipatch?fbclid=IwAR21Sy7YpQYVw-otDE2ah9aPf-DNslt0jUw4xJMFcKxAXRyo_JkWNQ7TcYI
____________________________________________
ActiPatch is the drug-free solution for pain. It interrupts abnormal pain signaling in the nerves. You won't feel anything but relief. $$$ BACK GUARANTEE USA:
http://actipatch.com 📷
#painmanagement #painrelief #clinicallyproven #FDAcleared #backpainrelief #NeckPainRelief
No More Dangerous, Addictive or Expensive Drugs.
https://twitter.com/ActiPatch/status/1752421581769363689?s=20
___________________________________________________________________
ActiPatch®
@ActiPatch
ActiPatch reaches deep into the painful area to provide real relief at the source. Can be used 24/7. You won't feel anything but PAIN RELIEF.
$$$ BACK GUARANTEE OFFER USA:
http://actipatch.com 📷 #neckpainrelief #techneckrelief #painrelief #neckarthritisrelief #neckpain
https://twitter.com/ActiPatch/status/1745131740358729994?ref_src=twsrc%5Etfw%7Ctwcamp%5Etweetembed%7Ctwterm%5E1745131740358729994%7Ctwgr%5E811275876d36002daf58d004f9820350cd7adb08%7Ctwcon%5Es1_&ref_url=https%3A%2F%2Finvestorshub.advfn.com%2Fboards%2Fread_msg.aspx%3Fmessage_id%3D173613351
ITS coming to BIEL $$$$$$$$$$$$$$$$$$$!!!!!!!!!!!!!!!!!!!!!!!!
11/20/2023
Washington State poised to extend coverage for SCS
https://www.neuromodulation.org/news/washington-state-poised-to-extend-coverage-for-scs
________________________________________________________________
ActiPatch SA
February, 6 at 1:35 Am
Struggling with chronic pain? 🤕 ActiPatch® pain-relief device is clinically proven to relieve muscle and joint pain!¹?³
✅ Ideal for arthritis, back pain, knee pain, fibromyalgia, and more.²
🔍 Targeted, long-lasting pain relief in just 2-3 hours.¹
🔋 Lasts up to 720 hours for continuous comfort.
🚀 Small & lightweight.¹ Say goodbye to bulky equipment!
Get back to feeling your best with ActiPatch®, available at Dis-Chem Pharmacies, Clicks and leading pharmacies nationwide.
#ActiPatch #DrugFree #PainRelief #PainManagement #ChronicPainManagement #JointPainRelief #SportsInjuryRelief #BackPainRelief #KneePainRelief #ArthritisPainRelief #chronicpainrelief
https://www.facebook.com/watch/?v=1124676815379216
__________________________________________________________________
NANS Advocacy Results in HCSC Adding Closed-Loop Spinal Cord Stimulation to Coverage!!
https://www.neuromodulation.org/news/closed-loop-04172023
_______________________________________________________________
ActiPatch®
@ActiPatch
Get the sleep you deserve with relief from ActiPatch! ActiPatch doesn't just put a band-aid on pain. It dives deep with its Pulsed Shortwave Therapy & takes on pain at its root for sustained relief! Order at http://actipatch.com FREE SHIPPING. #painmanagement #painfreesleep
https://twitter.com/ActiPatch/status/1737209416749887575?ref_src=twsrc%5Etfw%7Ctwcamp%5Etweetembed%7Ctwterm%5E1737209416749887575%7Ctwgr%5E811275876d36002daf58d004f9820350cd7adb08%7Ctwcon%5Es1_&ref_url=https%3A%2F%2Finvestorshub.advfn.com%2Fboards%2Fread_msg.aspx%3Fmessage_id%3D173613351
___________________________________________________________
Chronic Pain, Fibromyalgia and Plantar Fasciitis Help --- ACTIPATCH!!!
https://www.facebook.com/groups/1795257327156301/?multi_permalinks=7709195185762456
_____________________________________________________________
SAI has Registered with FDA to Sell ActiPatch in USA and Canada for 2024
Establishment Registration and Device Listing
Establishment Name ....................... Reg number ..Current Reg Yr
AIRWAY SURGICAL APPL .CANADA 9611956 ...........2024
Nonthermal Shortwave Therapy Device Indicated For Over The Counter Use For The Treatment Of Pain / Repackager/Relabeler
SURGICAL APPL INDUSTRIES , INC. USA 1511629 2024
Nonthermal Shortwave Therapy Device Indicated For Over The Counter Use For The Treatment Of Pain
Repackager/Relabeler
KT Health, LLC ......................... UT/USA 3007282994 2024
Nonthermal Shortwave Therapy Device Indicated For Over The Counter Use For The Treatment Of Pain
(Airway Surgical is SAI's Canadian branch)
_________________________________________________________
PEMF Alzheimer’s Treatment Pilot Underway at Hackensack University Medical Center
https://www.hackensackmeridianhealth.org/en/info/geriatrics/evoke-trial
---------------------------------------------------------------------------------------
ActiPatch
Part of STADA MENA participation at Manama Heath Congress and Expo at Bahrain
Thanks team for your efforts. Ahmed El-Barbary, Sherif Al-Kady , MBA, Diksha Ahuja, Mohamed Hosny, Abdullah Hassan, Raghdaa Badr, Mohamed Taher, Mohamed Abassi
#stada #manamahealth #caringforpeopleshealth
STADA MENA
https://www.manamahealth.com/
----------------------------------------------------------------------------------------
BioElectronics Corporation’s Post
View organization page for BioElectronics Corporation
BioElectronics Corporation
3,331 followers
Both NSAID therapy and neuromodulation therapy using PSWT resulted in statistically and clinically important reductions in pain level and improvement in functionality associated with cervical osteoarthritis, when used for 4 weeks. However, the PSWT intervention demonstrated superior improvements in all outcome measures when compared to the etoricoxib therapy arm, including patient satisfaction rating and decreased use of rescue pain medication. These results suggest that neuromodulation using PSWT may be a superior pain treatment option, when compared to COX-2 NSAIDS for neck osteoarthritis, and as well, represents a non-invasive, non-pharmacologic treatment option.
Product samples are available to licensed medical care providers in the USA. Request via email - info[ @newbie00
https://www.linkedin.com/posts/bioelectronics-corporation_pulsed-shortwave-therapy-in-cervical-osteoarthritis-activity-7138985310968795136-SRFJ
https://link.springer.com/article/10.1007/s42399-020-00652-y
---------------------------------------------------------------------------------------------------
New product added
https://actipatch.com/buy-1
BIEL $$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$
-------------------------------------------------------------------------------------------------
Top5-USA.co
Top 5 Actipatch In The US
https://www.top5-usa.com/actipatch
------------------------------------------------------------------------------------------------------
RecoveryRX
BOSTON ORTHOPEDIC & RESPIRATORY EQUIPMENT, LLC.
https://www.bostonorthoresp.com/214-4_p_10155.html?referrer=rss
BIEL $$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$
-----------------------------------------------------------------------------------------------------------
This is just a few FACTS to help with INTELLIGENT DD and to INVEST in BIEL, which, i/we agree with this post worth a reasonable investment:
(https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172266874;; )
Top 50 Innovative Businesses: BioElectronics Corporation, Clym Environmental Services and Cornerstone Genomics
https://www.discoverfrederickmd.com/news/top-50-innovative-businesses-bioelectronics-corporation-clym-environmental-services-and-cornerstone-genomics
" RecoveryRx repairs and regenerates damaged cells by reducing pain and inflammation and accelerating blood flow. Whereas, TENS is only blocking pain signals and has no healing effect. The major difference between the two is that a TENS unit is a short term solution that “turns off” the pain signal but CANNOT perform the function of repairing damaged tissue like RecoveryRx. "
https://www.linkedin.com/posts/lauren-jarman-380a801a9_clinicallyproven-fdacleared-noninvasive-activity-7051200138563735553-Q9Zs
BIEL $$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$
-------------------------------------------------------------------------------------------
Watch till the end!
https://www.instagram.com/reel/Cvq8j0bILP4/?igshid=MzRlODBiNWFlZA==
BIEL $$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$
---------------------------------------------------------------------------------------------
7 anti-aging benefits of PEMF therapy
https://www.outlookindia.com/business-spotlight/anti-aging-benefits-of-pemf-therapy-news-259187;;
"Literally, there are so many benefits to a regular PEMF therapy session. Research by NASA and other bodies has found that PEMF therapy can deliver the following results:
Better circulation
Pain reduction
Improved muscle relaxation and performance
Decreased inflammation and swelling
Improved oxygenation in tissue
Enhanced cellular repair and recovery
Improved immune system
Better sleep "
https://higherdose.com/blogs/news/8-benefits-of-pemf-therapy?psafe_param=1&tw_source=google&tw_adid=634407957086&tw_campaign=18892036948&gad=1&gclid=CjwKCAjw44mlBhAQEiwAqP3eVqY1HlussPIpcLNFP0O10gqhWUrMI0VdqtspfI3FlKHqC0HkjB_OkBoCc08QAvD_BwE
BIEL $$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$
-------------------------------------------------------------------------------------
INTRODUCING
RecoveryRx Veterinary
Drug-Free Pain Relief Device
For Indoor and Outdoor Pets
https://rrxvet.carrd.co/
BIEL $$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$
----------------------------------------------------------------------------------------------------------
Once, pay ATTENTION Everyone -- NOT if, IMO, NHL, NFL, NBA, WBA, MLB, PGA, Lacross, etc...... adopts Actipatch as a must protocol, after all those HITS, CHECKS, TRIPS, LIGAMENT PULLS/RIPS, etc.......Possibilities are ENDLESS !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
BIEL $$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$
---------------------------------------------------------------------------------------------
ATTENTION all the Respected, Smart, Intelligent Investors !!!!!!! Do your OWN, INTELLIGENT, THOROUGH DD, without ANY influence from KNOWN PAID BASHERS / LIARS / MANIPULAYOTS / MISINFORMERS !!!!!!!!! Make sure, if you decide to invest ( and to decide you MUST !! ) :
#1 -- Don't put all the money you are willing to invest in one basket ( buy only one stock ), be diverse......VERY IMPORTANT -- Do your OWN, INTELLIGENT DD !!!!!!!!!!!!!!!!
#2 -- If you decide/willing to buy BIEL shares, know, that this is a HIGH RETURN / HIGH LOSS RISK ratio, but the MIRACLE PRODUCT ( ACTIPATCH ) is the key !!!!
#3 -- if you decide/willing to buy BIEL shares, invest only as much as you are willing to loose, without being hurt, FINANCIALLY !!!!!!!!!!!!!!!!!
Good luck to all !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
BIEL $$$$$$$$$$$$$$$$$$$$$$$$$
DID I SEE A ONE MILLION SHARE ASK SLAP EARLIER TODAY??? THAT'S MORE LIKE IT BOYS AND GIRLS!!! NOW WE NEED TWENTY MORE SLAPS JUST LIKE THAT TO GET THE ASK BACK UP TO .0003. STEP UP TO THE PLATE AND SLAP!!!
If you are citing the OTC Markets Cromwell Coulson article, he is the President, CEO, and Director of the OTC Markets. His job is to make investors comfortable with the OTC so that they will spend more money. He is not going to tell you how many times Market Makers have been caught abusing their power / violating Shorting Regulations and that many times the violations go on for years and years before they are caught if they are ever caught.
SEC Charges Citadel Securities for Violating Order Marking Requirements of Short Sale Regulations
Washington D.C., Sept. 22, 2023 —
The Securities and Exchange Commission today announced settled charges against broker-dealer Citadel Securities LLC for violating a provision of Regulation SHO, the regulatory framework designed to address abusive short selling practices, which requires broker-dealers to mark sale orders as long, short, or short exempt. These records are routinely used by regulators in policing prohibited short selling activity. To settle the SEC’s charges, Miami-based Citadel Securities agreed to pay a $7 million penalty. According to the SEC’s order, for a five-year period, it is estimated that Citadel Securities incorrectly marked millions of orders
“Compliance with the order marking requirements of Reg SHO is a key component of regulatory efforts to curtail abusive market practices, including ‘naked’ short selling,” said Mark Cave, Associate Director of the SEC’s Division of Enforcement.
Goldman Sachs fined $3M by FINRA over mismarked short sales
Wed, Apr 5, 2023 10:36 AM
Goldman Sachs was fined $3 million by the Financial Industry Regulatory Authority (FINRA) for mismarking nearly 60 million short sell orders as long and related supervision failures. From 2015-18, Goldman Sachs’s automated trading software mismarked sell orders following a system upgrade intended to simplify order flow, according to FINRA.
Merrill to Pay $850K FINRA Fine Over Short Sale Violations
October 07, 2021 at 02:37 PM
Merrill misapplied the SEC-approved Multi-day Approach on at least 6,000 occasions, FINRA alleged. From September 2013 until July 2016, Merrill violated Rule 204 of Regulation SHO and FINRA Rule 2010. Also, from January 2005 until January 2015, Merrill violated Rule 200(f) of Regulation SHO.
LMAO, I think I DID answer it with the fact that a double zero stock price is still a JOKE, so no change in attitude that this investment IS a JOKE ---- even at the HIGH stock price of DOUBLE ZEROS!
How is this message board conversing with the 'true longs' ---- NOT FUN???!!!
One or two beauties, and this is going to climb fast. Announcements with guaranteed BIEL sales included will blow the top off.
‘Nuff said!
BUY $BIEL$
Once again, you didn’t answer my BIEL post. You scooted around the issue like you always do. It doesn’t surprise me. It’s expected.
‘Nuff said!
Geez, you are a nervous Nelly! An admitted agitator and going for the most posts ever on BIEL. Pathetic really.
‘Nuff said!
BUY $BIEL$
Don't let that fool get to you. They most likely own zero shares and are just here to agitate others.
You need to understand ihub has people working for them to pump under performing stocks like BIEL. All they want to see is a higher ranking on the most read, most posted, or even (but not possible) break out board.
Now Srinsocal, you know full well that those trades will be covered and closed well before the required time period, most likely within minutes. That is why there will not be any “fail to delivers” on the monthly short interest report ( the one that matters, as opposed to the daily report you are so fond of). This has been discussed as nauseam.
The point is that some one sold all of those shares at a very low price. Whether the MM had the shares in their account at the moment of the sale, or a minute, or a day later doesn’t change any of the facts.
>>> once we get out of the BIEL trips, I’ll expect a change of attitude.<<<
So double zeros are so great? LOL! Well. I guess it would be better than rock bottom .0001, where it has been trading lately.
Remember when this was trading 2 ticks from a penny and everyone was getting excited? Why the drastic drop to where it is now? What happened?
Maybe it was that everyone saw THIS, as it was posted to the stockholders in 2022, for what it was: https://investorshub.advfn.com/uimage/uploads/2023/8/20/yeqevsynergy.jpeg
KT-Recovery+Wave #97 on Amazon. TENS are the top sellers.
BIEL can spend another 20 years trying to market this junk, but it won't do any good.
You tell them to stop pretending, but pretending is all they have.
LOL. Frankly, they (whoever that is) don’t pay you enough. once we get out of the BIEL trips, I’ll expect a change of attitude.
‘Nuff said!
BUY $BIEL$
14 out of 23 trades today at .0001 or .0001(X)
>>>Pathetic really. Absolutely pathetic.<<<
I agree! ----- https://ih.advfn.com/stock-market/USOTC/bioelectronics-pk-BIEL/trades
Notice the final $20 trade to close this at .0002
Dude, you can kiss the baby. Promise me this. When BIEL gets out of the trips, you’ll be a cheerleader and that (how do you Americans say BASHER) will be turned around and you’ll praise BIEL. Fair enough?
‘Nuff said!!!
BUY $BIEL$
Followers
|
1056
|
Posters
|
|
Posts (Today)
|
34
|
Posts (Total)
|
328795
|
Created
|
05/18/05
|
Type
|
Free
|
Moderators misanthrope Capsule JustGoDeep toohot JNdouble1 gimmee greenbacks |
PHOENIX, June 13, 2018 (GLOBE NEWSWIRE) -- Uptick Newswire welcomed Andy Whelan, President of BioElectronics Corporation (OTC Pink:BIEL) ("the Company") back onto the "Stock Day" podcast. Andy spoke with Everett about their progress in the US market, UK market, the new product, the US FDA, and new distributors and potential partnership opportunities.
BioElectronics Corporation is a leader in non-invasive electroceuticals and the maker of an industry leading family of disposable, drug-free, pain therapy devices: ActiPatch(R) Therapy, over-the-counter treatment for back pain and other musculoskeletal complaints; RecoveryRx(R) Devices for chronic and post-operative wound care; Allay(R) Menstrual Pain Therapy. For more information, please visit http://www.bielcorp.com/
The Company is currently pursuing multiple US partnership opportunities that are partially contingent on additional FDA clearance for the treatment of musculoskeletal pain, back pain, knee pain, muscle, hip, carpal tunnel, etc. Whelan said,"Patience is key throughout this process. It's going as well as it can." Additionally, the Company anticipates solidifying deals with two new major distributors in the Asian and Eastern European markets.
The Company's product development and regulatory clearances are going well. Now, with pre-submission clearance, the 510(k) relief of musculoskeletal pain market clearance application will be filed by the end of June.
The US FDA has recently implemented an Innovation Program seeking "Breakthrough Devices" to Prevent and Treat Opioid Use Disorder. Opioids are routinely used for post-operative pain. Our United Kingdom ActiPatch User Registry accounts that 71% of opioid customers report a moderate (50%) to complete (100%) elimination in opioid medication use. The Company plans to submit its post-operative pain relief market clearance application into this program. The FDA's assistance, participation, and approval will provide credence and accelerate product market acceptance.
The Company has begun shipments of its new single box kinesiology tape product to be used for back, knee, hip, and muscles and joints in lieu of the back wrap, knee wrap and muscle and joint adhesives. The kinesiology tape is easier to use, reduces product costs, and retail shelf space requirements.
The Company is transitioning its United Kingdom over-the-counter sales and marketing from the front of the store to behind the counter to expand product availability from a few stores to all 14,000 pharmacies. Most pharmacies obtain daily product deliveries and most people in the UK qualify for free prescriptions.
Whelan is confident in the direction the Company is moving, and cites the unique nature of their products as a factor that helps the Company stand out in the global medical electronics industry. Whelan then said, "This is one busy little Company."
"Stock Day" host Everett Jolly stands by his assessment from his April interview with the company that the stock is very undervalued. BioElectronics Corporation trades on the OTC Pink market under the ticker symbol BIEL. Shares are currently selling at 0.0037, up over 100% since April.
For more details about the Company's recent FDA meetings, potential partnership opportunities, and attempts to combat the ongoing opioid crisis, follow the link below to hear the full interview.
https://upticknewswire.com/featured-interview-ceo-andrew-whelan-of-bioelectronics-corp-otc-pink-biel-3/ ;
About BioElectronics Corporation
BioElectronics develops and manufactures unique nonprescription affordable neuromodulation medical devices. The Company's technology platform is for the treatment of central sensitization, which is now widely accepted as the physiological explanation for many neurological disorders, and specifically chronic pain. Central sensitization is difficult, if not impossible, to address through pharmacotherapy without having a detrimental impact on normal physiologic function. Moreover, pharmacological and masking therapies (creams, heat patches, TENS etc.) have limited effectiveness for chronic pain due to their transient nature. BioElectronics' electromagnetic stimulation therapy has the distinct advantage of being safe, affordable, long lasting, and effective pain relief.
Contact: Paul Knopick, 940.262.3584, pknopick@eandecommunications.com
FREDERICK, MD., May 31, 2018 (GLOBE NEWSWIRE) — BioElectronics Corporation (OTC PINK: BIEL), maker of advanced medical devices announces that B. Braun Ltd, of Sheffield, UK has recently completed development of its same day surgical TOTAL Pathway program for joint replacements which includes BioElectronics medical devices. The program is being launched by B. Braun’s UK […]
FREDERICK, MD, May 29, 2018 (GLOBE NEWSWIRE) — BioElectronics Corporation (OTC PINK: BIEL), www.bielcorp.com reports that it has cancelled today’s scheduled US Food and Drug Administration meeting. “The FDA’s response to our questions, suggestions, and instructions are more than adequate for us to proceed with filing of the formal 510(k) Market Clearance Application,” stated Ian […]
FREDERICK, MD , May 11, 2018 (GLOBE NEWSWIRE) — BioElectronics Corporation (OTC PINK: BIEL), www.bielcorp.com is pleased to report on the outcome of its Pre-Submission meeting on May 9th, 2018 with the US Food and Drug Administration (US FDA). The FDA’s Pre-Submission Program is designed to organize and give guidance and feedback on clinical data and what […]
FREDERICK, MD, May 02, 2018 (GLOBE NEWSWIRE) — BioElectronics Corporation (OTC PINK: BIEL), www.bielcorp.com is pleased to announce that two meetings have been scheduled with the US Food and Drug Administration (FDA) to seek expanded over-the-counter (OTC) clearances for their drug-free, wearable medical devices. The first meeting will take place on May 9th, 2018 to […]
PHOENIX, April 26, 2018 (GLOBE NEWSWIRE) — Uptick Newswire was thrilled to have Keith Nalepka, VP of Marketing & Sales at BioElectronics (OTC Pink:BIEL) (“the Company”), return to the “Stock Day” podcast. The company has been working hard lately to expand the United Kingdom market with B. Braun in the surgical market and the product […]
FREDERICK, MD, March 19, 2018 (GLOBE NEWSWIRE) — BioElectronics Corporation (OTC PINK: BIEL), www.bielcorp.com is pleased to announce the commencement of a clinical study investigating the efficacy of its RecoveryRx® device for postoperative pain management and recovery following total knee arthroplasty surgery. Currently there are 700,000 total knee replacement surgeries in the US alone and are projected to grow 673% to 3.5 million procedures per […]
PHOENIX, Jan. 22, 2018 (GLOBE NEWSWIRE) — The Uptick Newswire “Stock Day” podcast keeps investors up to date on the latest penny stock news by bringing transparency in the micro-cap side of the market. Connect with “Stock Day” and to over 600+ CEO interviews on the OTC, Pink Sheets and micro-cap news from around the world […]
FREDERICK, MD, Jan. 09, 2018 (GLOBE NEWSWIRE) — BioElectronics Corporation (OTC Pink: BIEL), the maker of advanced wearable consumer pain management medical device, ActiPatch, announced today that CARE Pharmacies has committed to introducing ActiPatch, Musculoskeletal Pain Therapy medical device to its patients. “With the current opioid crisis here in the United States, as pharmacists, we […]
FREDERICK, Md., Jan. 04, 2018 (GLOBE NEWSWIRE) — BioElectronics Corporation (OTC PINK: BIEL), www.bielcorp.com makes wearable, drug-free chronic pain therapy medical devices. It is pleased to announce that the UK’s government funded public health service, National Health System (NHS), has approved our application to cover and pay for ActiPatch® Musculoskeletal Pain Therapy. The NHS estimates that almost half […]
FREDERICK, MD, Dec. 12, 2017 (GLOBE NEWSWIRE) — BioElectronics Corporation (OTC Pink: BIEL), the maker of advanced wearable consumer pain management medical device, ActiPatch, announced today the launch of ActiPatch for Over-The-Counter, drug-free pain relief as an alternative to Opioids. ActiPatch is approved by the FDA for Over-The-Counter sales for the adjunctive treatment of pain […]
BioElectronics Receives FDA Pre-Submission Approval for its Relief of Musculoskeletal Pain Market Clearance Application
FREDERICK, MD , May 11, 2018 (GLOBE NEWSWIRE) -- BioElectronics Corporation (BIEL) , www.bielcorp.com is pleased to report on the outcome of its Pre-Submission meeting on May 9th, 2018 with the US Food and Drug Administration (US FDA). The FDA’s Pre-Submission Program is designed to organize and give guidance and feedback on clinical data and what regulatory pathway should be followed to get market clearance. The focus of the May 9 pre-submission meeting was in discussing the FDA’s feedback on the clinical outcomes and statistical techniques used in reporting the back-pain study.
Upon reviewing pre-submission information on the ActiPatch® back-pain study (https://clinicaltrials.gov/ct2/show/NCT03240146), the FDA provided positive feedback on the clinical results, and guidance on a 510(k) submission to obtain expanded market clearance for over-the-counter (OTC) treatment of musculoskeletal pain. This would make ActiPatch available as a drug-free, safe, pain relief option for the 126 million Americans (one in two adults) who are suffering with some form of musculoskeletal pain. While ActiPatch is already FDA cleared for treatment of pain from knee osteoarthritis (25 million) and plantar fasciitis (1 million annually), expanded market clearance would allow additional products for the back (42 million), neck (19 million), hip (9 million), shoulder (11 million), carpal tunnel (12 million) and many other musculoskeletal complaints.
The company was represented by their clinical R&D team comprising: Sree Koneru, Ph.D., VP Product Development, Ian Rawe, Director Clinical Research of BioElectronics (BIEL), Kenneth McLeod, Ph.D. Director of Clinical Science and Engineering Research, State University of New York at Binghamton and Richard Staelin, Ph.D. Professor Duke University. Dr. Koneru, who led the discussion, expressed confidence in the FDA’s constructive feedback. “We are pleased that the FDA viewed our data and statistical methods favorably. They have provided guidance on how to combine the back-pain study results, along with our previously cleared 510(k), into a single 510(k) submission for obtaining expedited expanded market clearance.”, he said.
An additional pre-submission meeting is scheduled with the FDA on May 29th, 2018 to seek expanded indications in a separate application for OTC treatment of pain and edema following surgical procedures for its RecoveryRx® medical device.
About BioElectronics Corporation
BioElectronics Corporation is a leader in non-invasive electroceuticals and the maker of an industry leading family of disposable, drug-free, pain therapy devices: ActiPatch® Therapy, over-the-counter treatment for back pain and other musculoskeletal complaints; RecoveryRx® Devices for chronic and post-operative wound care; Allay® Menstrual Pain Therapy. For more information, please visit www.bielcorp.com
BioElectronics VP of Sales Discusses Pre & Post-operative Pain Relief Surgical Program in "Stock Day" Interview
PHOENIX, April 26, 2018 (GLOBE NEWSWIRE) -- Uptick Newswire was thrilled to have Keith Nalepka, VP of Marketing & Sales at BioElectronics (OTC Pink:BIEL) ("the Company"), return to the "Stock Day" podcast. The company has been working hard lately to expand the United Kingdom market with B. Braun in the surgical market and the product opportunity from the recent National Health Service payment approval for its ActiPatch® medical device.
BioElectronics is with B. Braun Medical, Ltd.UK to initiate the "Total Pathways Program" program into B. Braun's 26 geographic markets. The program is for pre-habilitation (treatment that happens prior to surgery) and post-operative recovery. This new program will benefit the majority of the 160,000 UK annual knee, hip, or joint replacements patients. According to Keith, BioElectronics is not just trying establishing a brand, but "to establish the process to a standardize care for pre and post-operative pain."
The company is immensely proud of their team for getting their concept through to the National Health Service (NHS) in the UK. In addition to successes here, the company is hoping to utilize their overseas success by applying data to their US-based efforts.
There are some great potential partnerships currently being discussed at BioElectronics, with the closing of a significant deal just on the horizon.
BioElectronics Corp is approaching their upcoming FDA meetings with confidence. "We have the data to make a very strong case for both broader musculoskeletal and post-operative pain relief indications," said Nalepka. "It's an exciting time for the company, and a really cool little product."
For more details on the Total Pathways Program, news about a partnerships, and information about the company's upcoming meetings with the FDA, follow the link below to the full interview.
https://upticknewswire.com/featured-interview-vp-of-sales-keith-nalepka-of-bioelectronics-corp-otcpink-biel-3/ ;
About BioElectronics
BioElectronics Corporation is a leader in non-invasive electroceuticals and the maker of an industry leading family of disposable, drug-free, pain therapy devices: For more information, please visit www.bielcorp.com.
Contact: Paul Knopick, 940.262.3584, pknopick@eandecommunications.com
Safe Harbor Statement
Certain statements contained herein are "forward-looking statements," (as defined in the Private Securities Litigation Reform Act of 1995). BioElectronics Corp. cautions that statements and assumptions made in this news release constitute forward-looking statements; the company makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, and other estimates made by management. Actual results could differ from current projections or implied results. BioElectronics Corp. undertakes no obligation to revise these statements following the date of this news release.
About Uptick Newswire
Uptick Newswire is a private company reaching out to the masses keeping investors and shareholders up to date on company news and bringing transparency to the undervalued, undersold, micro-cap stocks of the market and is the sole producer of the Uptick Network "Stock Day" Podcast. The Uptick Network "Stock Day" Podcast is an extension of Uptick Newswire and has recently launched the Video Interview Studio located in Phoenix, Arizona.
Contact Information
Uptick Newswire LLC
Everett Jolly, CEO/Founder
602-441-3474
10000 N. 31st Avenue C307 Phoenix, AZ 85051
info@upticknewswire.com
www.upticknewswire.com
Release #:812-170554-rl-1141231: |
BioElectronics Up-Date |
Dear Fellow Shareholders, This letter is to report on our recent progress in marketing and product development. We have established the following:
We are continuing to solicit new international and domestic sales and marketing partners for distribution and licensing, while strengthening our relationship with existing partners. To aid in this effort we have engaged an accomplished sales and marketing pharmaceutical consultant to assist in introduction and negotiations of sales and marketing partnerships. US Market Clearance ActiPatch®, Musculoskeletal Pain Therapy We are in the process of expanding the US market clearance from relief of osteoarthritis of the knee pain and plantar fasciitis. Our goal is to obtain general clearance for musculoskeletal pain. To achieve this, we have submitted a chronic back pain clinical study to the US FDA as a formal Pre-Sub. The initial meeting with the FDA is tentatively scheduled for May 9th. Prior guidance from the FDA indicated that a third clinical study was required before expanding the current market indications to cover all musculoskeletal pain. We are hopeful that the process will be completed rapidly, however we will not have a good estimate of this market clearance date until the completion of the May 9th meeting. Postoperative Recovery and Pain We have submitted a formal Pre-Sub to the US FDA for guidance in obtaining market clearance for the palliative treatment of postoperative pain and edema. The application is supported by postoperative clinical studies on breast augmentation and caesarean section. Marketing Expansion We believe that expanded market clearance from the FDA will enhance the market value and attractiveness of the ActiPatch product line. Our economic and clinical studies for the National Health Services allowed us to gain a drug tariff listing for reimbursement in England and Wales allowing the following:
The ActiPatch registry studies report that people buy the device because it is effective, drug-free, has no harmful side effects and overall improves quality of life. We are continually working to solve existing minor issues with the use of ActiPatch. To improve the product, we are introducing custom-design kinesiology tape strips to attach the device to the body. Aside from improving user comfort, this allows us to promote a single multi-purpose box with the added benefit of reducing retail shelf space. We believe this will then allow us to sell the 7-day trial devices from pharmacy shelves. B. Braun UK This is an important development for BioElectronics. B Braun has been using RecoveryRx to improve recovery following joint replacement for many years, although in limited surgeries. However, new advances in day surgery for joint replacement have expanded our opportunity. B. Braun has recently completed a pilot program in the UK evaluating day for joint replacement. The United Kingdom's Group day surgery program for knee and hip replacement patients and is now being implemented on a national basis. Currently there are 80,000 procedures per year involving B Braun. The "fast-track" same day hip and knee replacements are being supported by hospital physiotherapy teams visiting the patient at home and communicating using a special wireless technology tablet. Upon hospital discharge, each patient will be given an ActiPatch medical device and a prescription for 6 additional devices to help accelerate recovery and mitigate the postoperative pain. A similar program is in development for spinal surgeries. On an international level, B. Braun's 54,000 employees are in 60 countries and are separated into additional divisions for hospital care, surgical products, outpatient care, and home care services. It is anticipated that B. Braun's German Group will roll out the same day hip and knee replacement program in the next few months.
Smart Insole – Heel Pain Relief We have redesigned the Smart™ Insole plantar fasciitis insole to enhance user comfort. We are awaiting a written License and Supply Agreement for the product. Clinical Research to Expand Market Clearance and Acceptance Allay®, Menstrual Pain Therapy 28% of women are in the menstrual phase of life and 60% have moderate to severe menstrual pain, or 17% of women. Previously our medical devices were classified as high risk class III by the US FDA. While our existing pilot clinical study for menstrual pain reported exceptional results for menstrual pain, to publish a clinical study and obtain US market clearance, we are collaborating with the University Hospital at Birmingham, UK. The researchers here are world renowned thought leaders in women's health and are conducting a double-blind randomized controlled trial to evaluate the efficacy of ActiPatch in reducing menstrual pain (clinicaltrials.gov listing NCT03394547). You can view the existing clinical evidence and our commercials at https://www.myallay.com/ Prevention of Episodic Migraines Headaches Migraines affect 36 million men, women and children in the United States alone. The facts are:
Chronic pain is now widely understood to be due to central sensitization, which leads to exaggerated pain perception. Migraine is no exception; since it is well known that sensitization of the trigeminovascular pain pathway can occur during a migraine attack. There is pilot data that ActiPatch can help mitigate this sensitization, so a study has been completed to determine the efficacy of ActiPatch in preventing chronic, episodic migraines. The data from the study will be analysed in the next few weeks. We believe this data will allow us to work towards developing a product as a migraine therapy and allowing us to obtain market clearance. Postoperative Recovery and Pain Working with our distributor in Lebanon we are conducting a double blind placebo randomized controlled trial on total knee replacement (clinicaltrial.gov NCT03395444). Through our long standing association with B. Braun UK, RecoveryRx has been determined to be a valuable aid in joint replacement surgery. This clinical study will allow us to gain worldwide recognition and allow for expanded marketing and acceptance of the RecoveryRx as a standard of post-operative care following joint replacement. Interstitial Cystitis (Overactive Bladder and Pelvic Pain) This study is a University of Texas, McGovern Medical School sponsored double blind randomized controlled trial. The goal is to determine how well the ActiPatch therapy works in treating patients with interstitial cystitis, bladder pain syndrome and overactive bladder. Interstitial cystitis and bladder pain syndrome are chronic bladder health conditions that greatly affect quality of life. These conditions create intermittent feelings of pain and pressure in the bladder area. The study is expected to recruit 60 women who are urology patients of the University's hospital. At least 35 million Americans have overactive bladder. Lower urinary tract symptoms, urgency, and pelvic pain are common complaints to urologists and primary care physicians. Additional Bioelectronic Product Opportunities As we develop the organizational structure we envision additional opportunities in chronic wounds, neuropathy, hypertensive therapy, etc. Most importantly future growth is not dependent on large capital outlays for research and development. Immediate Sales Growth We anticipate imminent solid sales growth from the following programs:
Thank you for your support. Sincerely,
______________________ |
FREDERICK, MD., May 31, 2018 (GLOBE NEWSWIRE) — BioElectronics Corporation (OTC PINK: BIEL), maker of advanced medical devices announces that B. Braun Ltd, of Sheffield, UK has recently completed development of its same day surgical TOTAL Pathway program for joint replacements which includes BioElectronics medical devices. The program is being launched by B. Braun’s UK Group to improve care and reduce the UK healthcare cost of its 160,000 annual hip and knee replacement procedures.
The “fast-track” same day hip and knee replacements are being supported by hospital physiotherapy teams visiting the patient at home and communicating using a specialized wireless tablet. Each patient will be given an ActiPatch medical device and a prescription for 6 additional ActiPatch devices. A similar program is being implemented for spinal surgeries.
Phil Cleary, Senior Product Group Manager, stated that “our TOTAL Pathway program enhances our commitment to patient safety, post-operative care, as well as significantly reducing healthcare costs and hospital stays.” Treating post-surgical pain requires a multifaceted approach. In trials, ActiPatch was well received and produced positive outcomes. We look forward to making this program a success, in the UK and other countries where B. Braun operates.
About BioElectronics Corporation
BioElectronics Corporation is a leader in non-invasive electroceuticals and the maker of an industry leading family of disposable, drug-free, pain therapy devices: For more information, please visit www.bielcorp.com.
About B. Braun Medical Ltd
B. Braun Medical Ltd, UK, https://www.bbraun.co.uk/ is a member of the B. Braun Group, https://www.bbraun.com/en.html one of the world´s leading healthcare companies. On an international level, B. Braun’s 54,000 employees are in 60 countries and are separated into additional divisions for hospital care, surgical products, outpatient care, and home care services.
Keep in mind partners are happening and licensed ones at that.
The back study will not go in as a new submission, it is included in the knee and ankle submission so this will happen quicker than most would believe. Well actually the back study will be added to the prior submission, I don't want to confuse you
Watch how huge the Co-Branding gets. How many names besides Pain Gear?
Increasing shareholder value=7 components of shareholder value.
• Revenue
• Operating Margin
• Cash Tax Rate
• Incremental Capital Expenditure
• Investment in Working Capital
• Cost of Capital
• Competitive Advantage Period
Within the next 120 days BIEL will have in place-
Full body clearance minus the Migraine, anticipated clearance at a later date based upon the fact that this is a preventative study and the patients must have signs of a migraine coming, this study is a little more complicated.
Licensed partners (Major)
Equity partners
At least 2 huge retail chains
Let’s add on a few more distributors. Why not? Lol
NHS-first week of April, keep in mind not the only week, this is lifetime!
There will be other EU States that will duplicate the NHS and this will be coupled with licenses being sold to partners. What price, how much in royalties will soon be determined.
The August financials will and should be the strength of evidence that a certain person has established a supply chain that will be second to none.
I should mention that sales makeup only one component of the revenue stream, this is where my opinion may differ from the good posters on the BIEL board.
Revenue is the total amount taken in by a business in a set period of time.
This can include royalties, license fees and equity from partners and sales.
BIEL cannot have millions in sales without including the other revenue streams mentioned above.
My revenue forecast including sales may be different than others.
Great rewards will follow in due time. Waiting on the FDA protocol. Which means pre-submission. Guidance, rules and timing will be part of the protocol.(Looks like May-June clearance.)
Migraine clinical results will still be the huge one for the FDA protocol.(August-September clearance on positive results.)
NHS is the first of many EU States getting on board. Pretty good health systems across the pond. Sweden next!
The back pain study will obtain US FDA clearance for relief of musculoskeletal pain. Migraine headaches are not musculoskeletal. Migraines and musculoskeletal pain are both neurological disorders. Two FDA clearances!!!!!!!!!!!!!
SEC-much ado about nothing!
Partners-much ado about something!
12/7/2017 - Try and Tell US Launch, gets a 7 Day ActiPatch to US residents for shipping and handling costs of $4.95
12/7/17 - BIEL closes a deal with ANDA for National Distribution, ANDA has 60,000 commercial customers and is owned by TEVA Pharma, TEVA has extensive business dealings with the NHS
1/4/2018 - ActiPatch gains admission to the UK NHS Drug Tariff as a covered medical device, The NHS is the largest single healthcare delivery organization in the world
1/9/2018 - CARE Pharmacies will be handling the ActiPatch, CARE is an organization of 90 pharmacies in 17 states, CARE will be educating patients on the benefits of drug-free pain relief through Pain Consultations
1/16/2018 - Allay Menstrual Clinical Study is fully enrolled, taking place at the prestigious Birmingham Women's Hospital,an NHS Foundation Hospital
1/22/2018 - BIEL signs deal with Performance Health, 120 outside sales reps, 40 inside reps, KN interview
1/22/2018 - BIEL signs deal with MundiPharma in Australia and 8 other countries, Mundi is associated with Purdue Pharma, KN interview
1/22/2018 - Back Pain Study is complete, BIEL has dialogue ongoing with FDA for submission of Study to expand ActiPatch indications, KN interview
1/22/2018 - Migraine Study will get the full attention of staff now that the Back Study has been completed
1/22/2018 - BIEL in talks with Walmart
1/22/2018 - Meeting scheduled with CVS
This is the last 2 months of activity for BIEL. Any other OTC company would be dancing in the Street if they had accomplished this much in the last year.
The NHS Approval has opened new doors for BIEL and will continue to do so for many years.
FREDERICK, Md., Jan. 04, 2018 (GLOBE NEWSWIRE) -- BioElectronics Corporation (OTC PINK: BIEL), www.bielcorp.com makes wearable, drug-free chronic pain therapy medical devices. It is pleased to announce that the UK’s government-funded public health service, National Health System (NHS), has approved our application to cover and pay for ActiPatch® Musculoskeletal Pain Therapy. The NHS estimates that almost half of the 50 million UK adults may be living with chronic-pain¹, which is why there are more than 100,000 physician visits every day for musculoskeletal pain alone².
The ActiPatch is a drug-free, wearable medical device that regulates peripheral nerve activity to provide pain relief. The NHS based its decision considering strong clinical evidence and a health economics study, which found that ActiPatch significantly decreased pain and improved quality of life, while reducing overall healthcare costs by 42% (58.5% reduction in physician appointment costs, 35% reduction in prescription medication costs).
“This is a major win for pain sufferers in the UK, since they will now be able to obtain a prescription for ActiPatch, the cost of which will be covered by the government,” stated Ian Rawe, Ph.D., Director of Clinical Research at BioElectronics. “We commend this move by the NHS, as this will open up the doors for reimbursement in the US and other managed care markets. This will likely have a tremendous impact on our sales and marketability of the product in the UK and elsewhere,” said Keith Nalepka, VP of Sales & Marketing at BioElectronics.
With the addition of ActiPatch to list of approved treatments, chronic pain sufferers now have access to paid safe, drug-free chronic pain relief. The ActiPatch will be listed for payment coverage in April.
About BioElectronics Corporation
BioElectronics Corporation is a leader in non-invasive electroceuticals and the maker of an industry leading family of disposable, drug-free, pain therapy devices: For more information, please visit www.bielcorp.com.
References
1 NHS, "NHS Choices," January 2018. [Online].http://www.actipatch.com/actipatch/wp-content/uploads/2014/11/ActiPatch-3-month-Cost-Study-Final.pdf
Available: https://www.nhs.uk/news/medical-practice/almost-half-of-all-uk-adults-may-be-living-with-chronic-pai....
2 Arthritis Research UK, "Muscloskeletal Matters," Keele University, 2009
ActiPatch Cost Assessment Study Used By UK's NHS
http://www.actipatch.com/actipatch/wp-content/uploads/2014/11/ActiPatch-3-month-Cost-Study-Final.pdf
This improvement translated into reduced utilization of healthcare services, leading to a 36.8% reduction in health care costs to the NHS over a 3-month period, even after accounting for the cost of the ActiPatch device
Conclusion
Utilizing ActiPatch® as a chronic pain therapy treatment improves patient quality of life, while reducing the economic burden to the NHS.
"Almost half the adult population is living with chronic pain," the Daily Mail reports. A major new review suggests that around 28 million adults in the UK are affected by some type of chronic pain (pain that lasts for more than three months). Read More Link
https://www.nhs.uk/news/medical-practice/almost-half-of-all-uk-adults-may-be-living-with-chronic-pain/
February 06, 2017 09:05 ET
FREDERICK, MD--(Marketwired - Feb 6, 2017) - BioElectronics Corporation (OTC PINK: BIEL), the maker of wearable pain therapy devices, announced today that it has received over-the-counter use market clearance from the US FDA for ActiPatch® for the adjunctive treatment of musculoskeletal pain related to (1) plantar fasciitis of the heel; and (2) osteoarthritis of the knee.
BioElectronics is an electroceutical company that develops wearable, neuromodulation devices to safely mitigate neurological diseases and improve quality of life. Our innovative pulsed shortwave therapy technology (PSWT) that uses low power pulsed electromagnetic fields regulate electrical activity of the nervous system. The neuromodulation basis of PSWT presents significant opportunities for BioElectronics to develop optimized technology for diabetic neuropathy, postoperative surgery, chronic wounds, and other applications.
Our current OTC product line includes ActiPatch® Musculoskeletal Pain Therapy, Allay® Menstrual Pain Therapy, Smart Insole™ Heel Pain Therapy, and RecoveryRx® Post-operative and Chronic Wounds Therapy. The US FDA clearance is for our flagship product the ActiPatch® Musculoskeletal Pain Therapy, developed to relieve chronic pain. ActiPatch is a drug-free, wearable nonprescription medical device that provides 720-hours (90, 8-hour treatments) of on/off therapy for $30.00 retail. Most users obtain relief with only 8 hours per day of use, so the device will generally last several months, depending on use. ActiPatch Provides:
About BioElectronics Corporation
BioElectronics Corporation is a leader in non-invasive electroceuticals and the maker of an industry leading family of disposable, drug-free, pain therapy devices: For more information, please visit www.bielcorp.com.
How to Order an ActiPatch®?
Visit tryactipatch.com to place your order for the ActiPatch® today.
www.tryactipatch.com
BioElectronics Corporation
301-874-4980
info@bielcorp.com
4539 Metropolitan Court
Frederick, MD 21704
ActiPatch Healthcare Utilization Study Link
http://www.harmonyhealth.se/wp-content/uploads/2017/10/ActiPatchHealthcareCostStudy.pdf
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |